Supportive Care in Cancer

, Volume 19, Issue 6, pp 859–863

A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients

Authors

  • Haeseong Park
    • Department of Internal Medicine Residency ProgramVirginia Commonwealth University Health System
  • Gwendolyn L. Parker
    • Massey Cancer Center Cancer Prevention and Control ProgramVirginia Commonwealth University Health System
  • Cecelia H. Boardman
    • Department of Obstetrics and GynecologyVirginia Commonwealth University Health System
  • Monica M. Morris
    • Department of Radiation OncologyUniversity of Virginia Radiation Oncology
    • Massey Cancer Center Cancer Prevention and Control ProgramVirginia Commonwealth University Health System
    • Palliative Care Research and Medicine, Division of Hematology/Oncology and Palliative CareThomas Palliative Care Unit
Short Communication

DOI: 10.1007/s00520-011-1099-7

Cite this article as:
Park, H., Parker, G.L., Boardman, C.H. et al. Support Care Cancer (2011) 19: 859. doi:10.1007/s00520-011-1099-7

Abstract

Background

We tested if magnesium would diminish bothersome hot flashes in breast cancer patients.

Methods

Breast cancer patients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency × severity) at baseline was compared to the end of treatment.

Results

Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on anti-depressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p = 0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p = 0.04. Of 25 patients, 14 (56%) had a >50% reduction in hot flash score, and 19 (76%) had a >25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial.

Conclusions

Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost ($0.02/tablet) were minimal. A randomized placebo-controlled trial is planned.

Keywords

MenopauseHot flashesBreast cancerSurvivorshipDrug treatment

Copyright information

© Springer-Verlag 2011